Skip to main content
SINT logo

SINT · Sintx Technologies, Inc.

Track SINT — free
$1.35 -0.20 (-12.66%) At close · Nov 13
Market Cap
$10.17M
Shares
7.56M
Volume · Nov 13 77.62K Avg daily vol (3M) 49.39K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.35 Open$1.45 Day$1.34–1.53 52W close$1.35–4.26 Avg vol 30d39K Short int128K · 1.7% of shares · 7.3d Short vol63% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Latest documents

2026
Nov 5
Current report 8-K
Revenue surged as losses narrowed

SINTX Technologies, Inc. reported third-quarter revenue of approximately $2.2 million versus $208,000, net loss of approximately $1.6 million, down 55%, and completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System.

Financial results, Regulation FD disclosure
4 source passages
SALT LAKE CITY, Utah – November 5, 2026 – SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a global leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced its financial results and business highlights for the third quarter ended September 30, 2026. For the three months ended September 30, 2026, total revenue increased to approximately $2.2 million, compared with $208,000 during the prior-year period Net loss decreased 55% to approximately $1.6 million, compared with $3.5 million during the prior-year quarter Completed the limited-use release of the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System, initiated in the first quarter of 2026 Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises 315%, but going-concern doubt remains

SINTX Technologies reported total revenue growth of 315% for the nine months ended September 30, 2026, while net loss was $7.1 million and operating cash use was $6.6 million; substantial doubt remains about its ability to continue as a going concern.

Revenue $2.19M ▲ 952.9% Net loss $1.6M Diluted EPS -$0.24
Read from the MD&A section
4 source passages
SINTX Technologies is an advanced ceramics company formed in December 1996 that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. For the nine months ended September 30, 2026, total revenue increased $2.3 million, or 315%, compared to the same period in 2025. For the nine months ended September 30, 2026 and 2025, we incurred net losses of $7.1 million and $8.1 million, respectively, and used cash in operating activities of $6.6 million and $6.2 million, respectively. Management has concluded that substantial doubt remains regarding our ability to continue as a going concern for a period of one year from the date these condensed consolidated financial statements are issued. Open the document at this passage
Oct 30
Proxy statement DEF 14A
Proxy statement

SINTX Technologies, Inc. will hold its annual meeting on December 9, 2026, to elect Mark Anderson and Gregg Honigblum as Class III directors through 2029, ratify Tanner LLP, approve advisory executive compensation, and authorize possible adjournments.

Read from the first part of this long document
Oct 9
Current report 8-K Events of Oct 8
Other events

SINTX Technologies, Inc. received $2,014,645.22 from funded exercises and related exchanges involving 941,423 Class B warrant shares at $2.14 per share, issued 651,204 common shares and pre-funded warrants for 290,219 shares, and ended with no Class B warrants outstanding.

Oct 1
Current report 8-K
Financial results, Regulation FD disclosure

SINTX Technologies, Inc. reported preliminary, unaudited revenue of $2.2 million for the quarter ended September 30, 2026, including approximately $2.1 million in product sales. It intends to call Class B Warrants covering approximately 1.88 million shares.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.31M
Trailing 12 months
Net income (TTM)
−$9.34M
Trailing 12 months
Revenue growth YoY
+952.9%
Year over year
Operating margin
-303.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-91.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.95M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+124.9%
Year over year · more shares
Price change (1Y)
-56.0%
Trailing year
Short interest
1.7%
Latest settlement · 7.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −37%
below
Price vs 50-day avg −25%
below
RSI (14) 28
oversold
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −23%
trailing
6-month return −45%
trailing
YTD return −65%
this year
Relative strength −45%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
20 of 21 funds reported for Sep 30 · net -4.5K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.70% of shares out · ▼ -5.9% MoM · 7.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
21 holders — mid 3-yr range
Squeeze score 49
elevated · 0–100
Fundamentals
Strong
Revenue growth −65%
Y/Y
Gross margin 45%
contracting
EPS growth +59%
Y/Y
Free cash flow $-8.8M
Buyback $366.9K
remaining
Balance sheet $4.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 70%
annualized · 1-yr
Max drawdown −68%
past year
ATR 10.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 11, 2026
Total revenue · fourth quarter of 2026 Maintained $1M – $1.3M
Jun 30, 2026 $1M – $1.3M changed to Aug 11, 2026 $1M – $1.3M
prior qtr $2.19M midpoint −47.5% QoQ

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−37% Bearish
Price vs 50-day avg
−25% Bearish
RSI (14)
28 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Distributing
20 of 21 funds reported for Sep 30 · net -4.5K sh shares · +3 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
1.70% of shares out · ▼ -5.9% MoM · 7.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
21 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $4
vs 200-day avg -37% vs 50-day avg -25%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SINT
Sintx Technologies, Inc.
this stock
$10.17M -65.2% -64.7% — 1.7%
ABT
Abbott Laboratories
$187.95B -13.4% +5.7% 40.5 1.1%
MDT
Medtronic plc
$131.57B +7.1% +8.4% 25.3 1.8%
SYK
Stryker Corp
$117.88B -11.9% +11.2% 33.0 1.7%
BSX
Boston Scientific Corp
$64.27B -53.5% +12.5% 18.8 2.4%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
21
% held
12.7%
Reported
20 of 21
Top holder
Bleichroeder LP
Held Float
View
Held by Funds
Fund positions
6
View
Short & Settlement
Short Interest Falling
Shares short
128.4K
Days to cover
7.3d
Change
-8.0K sh
View
Short Volume
Short vol %
63%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
1.5K
Value
$3.2K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
65.1%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$1.0M
Net income (FY)
$-10.4M
EPS diluted
$-6.16
View
Buybacks
Authorized
$500.0K
Remaining
$366.9K
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
18

SINTX Technologies reported total revenue growth of 315% for the nine months ended September 30, 2026, while net loss was $7.1 million and operating cash use was $6.6 million; substantial doubt remains about its ability to continue as a going concern.

View
Proposed Sales
Value
$688.8K
Shares
157.2K
Filed
Feb 27, 2025
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View

Performance

5D 20D 120D MTD YTD
SINT -13.8% -22.7% -44.7% -20.9% -65.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY -16.4% -21.5% -45.2% -20.7% -75.8%

Capital returns

Buyback program · as of Jun 30, 2026
Authorized
$500,000
Spent (derived)
$133,065
Remaining
$366,935
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1269026 CUSIP 829392703 13F (30d) 25 filings 16 filers Visit website Investor relations